ReviewBritish dental journal2015
New cancer therapies and jaw necrosis.
Review in British dental journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Interventions for managing medication-related osteonecrosis of the jaw.The Cochrane database of systematic reviews · 2022Pooled it
- Interventions for managing medication-related osteonecrosis of the jaw.The Cochrane database of systematic reviews · 2017Pooled it
- Location and Gender Differences in Osteonecrosis of the Jaws in Patients Treated with Antiresorptive and Antineoplastic Drugs Undergoing Dentoalveolar Surgical, Systematic Review with Meta-Analysis and Trial Sequential Analysis.Journal of clinical medicine · 2023Review
- Antiresorptive medication in oncology: the clinical and dental profile of patients in a reference center.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2021Article
- Photodynamic Therapy as an adjunct in the Treatment of Medication-Related Osteonecrosis of the Jaw: A Case Report.Journal of lasers in medical sciences · 2021Article
- Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association.International journal of environmental research and public health · 2020Article
- Deciphering novel chemotherapy and its impact on dentistry.British dental journal · 2020Article
- MRONJ risk of adjuvant bisphosphonates in early stage breast cancer.British dental journal · 2018Article
- Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?BioMed research international · 2018Article
- Denosumab - a new medication in the treatment of postmenopausal osteoporosis.Przeglad menopauzalny = Menopause review · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteonecrosis of the jaw (ONJ) has a number of causes, the most familiar being radiation or bisphosphonate induced. Various other novel anti-neoplastic and bone-targeting therapies that can also cause jaw necrosis have recently become available. This has led to the suggested acronym MRONJ for medication-related osteonecrosis of the jaw. This article summarises the available information on these drugs and their implications for the dental surgeon.
Indexed as
Identifiers
26361116What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.